Should I buy or sell Soleno Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SLNO shares. View SLNO analyst ratings or view top-rated stocks .

What is Soleno Therapeutics' stock price target for 2024?

3 equities research analysts have issued 12-month target prices for Soleno Therapeutics' shares. Their SLNO share price targets range from $35.00 to $40.00. On average, they anticipate the company's share price to reach $38.00 in the next year. This suggests a possible upside of 31.3% from the stock's current price. View analysts price targets for SLNO or view top-rated stocks among Wall Street analysts .

How have SLNO shares performed in 2023?

Soleno Therapeutics' stock was trading at $1.98 at the start of the year. Since then, SLNO stock has increased by 1,361.6% and is now trading at $28.94. View the best growth stocks for 2023 here .

When is Soleno Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024. View our SLNO earnings forecast .

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) released its earnings results on Tuesday, November, 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by $0.33.

When did Soleno Therapeutics' stock split?

Soleno Therapeutics shares reverse split before market open on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , SCYNEXIS (SCYX) , OPKO Health (OPK) , ADMA Biologics (ADMA) , Matinas BioPharma (MTNB) , Miragen Therapeutics (MGEN) , Vaxart (VXRT) , Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD) .

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (32.06%), Carlyle Group Inc. (22.96%), Adage Capital Partners GP L.L.C. (13.28%), RA Capital Management L.P. (12.40%), Silverarc Capital Management LLC (3.70%) and Emerald Advisers LLC (2.49%). Insiders that own company stock include Bhatnagar Anish , Jack W Schuler , James H Mackaness , Kristen Yen and Perceptive Advisors Llc. View institutional ownership trends .

How do I buy shares of Soleno Therapeutics?

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Soleno Therapeutics Stock Price, News & Analysis (NASDAQ:SLNO)

$28.94

-0.89 (-2.98%)

(As of 12/4/2023 ET)

Compare

Today's Range: $28.28
▼
$30.53
50-Day Range: $20.67
▼
$29.83
52-Week Range: $0.85
▼
$30.53

Volume: 389,262 shs
Average Volume: 394,074 shs
Market Capitalization: $882.67 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $38.00

Soleno Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 31.3% Upside
$38.00 Price Target
Short Interest: Healthy
3.33% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.55
Upright™ Environmental Score
News Sentiment: -0.13
Based on 8 Articles This Week
Insider Trading: Acquiring Shares
$15.12 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.43) to ($1.29) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

122nd out of 952 stocks

Electromedical Equipment Industry

2nd out of 21 stocks

3.5

Analyst's Opinion

Consensus Rating
Soleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $38.00, Soleno Therapeutics has a forecasted upside of 31.3% from its current price of $28.94.
Amount of Analyst Coverage
Soleno Therapeutics has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.33% of the float of Soleno Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Soleno Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Soleno Therapeutics has recently decreased by 15.03%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Soleno Therapeutics does not currently pay a dividend.
Dividend Growth
Soleno Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Soleno Therapeutics has received a 73.45% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for genetic diseases" and "Basic medical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Soleno Therapeutics is -0.55.

1.0

News and Social Media Coverage

News Sentiment
Soleno Therapeutics has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Soleno Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 12 people have searched for SLNO on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Soleno Therapeutics insiders have bought 727.65% more of their company's stock than they have sold. Specifically, they have bought $15,115,340.00 in company stock and sold $1,826,287.00 in company stock.
Percentage Held by Insiders
28.80% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Soleno Therapeutics are expected to grow in the coming year, from ($2.43) to ($1.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Soleno Therapeutics is -8.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Soleno Therapeutics is -8.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Soleno Therapeutics has a P/B Ratio of 22.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Soleno Therapeutics Stock (NASDAQ:SLNO)

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

SLNO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SLNO Stock News Headlines

December 5, 2023 | americanbankingnews.com

Soleno Therapeutics, Inc. (NASDAQ:SLNO) CFO James H. Mackaness Sells 4,186 Shares of Stock

December 5, 2023 | americanbankingnews.com

Soleno Therapeutics, Inc. (NASDAQ:SLNO) CEO Bhatnagar Anish Sells 27,716 Shares of Stock

December 5, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

December 3, 2023 | americanbankingnews.com

Soleno Therapeutics, Inc. (NASDAQ:SLNO) CEO Sells $696,387.36 in Stock

December 3, 2023 | americanbankingnews.com

Soleno Therapeutics (NASDAQ:SLNO) Sets New 52-Week High at $30.42

December 1, 2023 | finance.yahoo.com

Insider Sell Alert: CFO James Mackaness Sells 8,081 Shares of Soleno Therapeutics Inc (SLNO)

November 28, 2023 | finance.yahoo.com

3 Biotech Stocks With Big-Time Breakthrough Potential

November 26, 2023 | seekingalpha.com

Soleno Therapeutics: Impressive Data, But Never Forget Amarin

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 21, 2023 | markets.businessinsider.com

4 Analysts Have This to Say About Soleno Therapeutics

November 10, 2023 | markets.businessinsider.com

Undervalued Potential: Soleno Therapeutics’ Promising Prospects and Upward Price Target Revision

November 7, 2023 | morningstar.com

Soleno Therapeutics Inc SLNO

November 7, 2023 | finance.yahoo.com

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 3, 2023 | msn.com

Soleno Therapeutics (SLNO) Price Target Increased by 14.43% to 37.74

October 16, 2023 | finance.yahoo.com

The Ten Most-Shorted Stocks Include Huge Market Movers In 2023

October 6, 2023 | finance.yahoo.com

Xerox, Mastercraft Boat, and More Stocks See Action From Activist Investors

October 5, 2023 | msn.com

Soleno Therapeutics (SLNO) Price Target Increased by 162.16% to 32.98

October 4, 2023 | finance.yahoo.com

Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium

October 4, 2023 | finance.yahoo.com

Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium

October 3, 2023 | msn.com

Meet Soleno Therapeutics, The Company Whose Hunger Suppressant Sent Shares Flying 505%

October 2, 2023 | finance.yahoo.com

Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 29, 2023 | msn.com

Soleno Therapeutics' 10% owner buys $15M worth of stock